- Chemopharm wins 2020 ASEAN Business Award
Chemopharm, an Everlife company, was recently awarded the ‘2020 ASEAN Business Award’ for their outstanding performance in the ASEAN Priority […]
- CPC Diagnostics launches first ICMR approved COVID-19 CLIA antibody test in India
Chennai, May 20, 2020 – CPC Diagnostics (‘CPC’), Chennai, a portfolio company of Everstone backed healthcare platform Everlife Holdings Pte. […]
- Chemopharm appointed as Exclusive Channel Partner of PAC in Malaysia
October, 2019 – Chemopharm Sdn Bhd, an Everlife investment and leading laboratory and medical devices distributor headquartered in Malaysia, is […]
- Everlife joins the Asia Pacific Medical Technology Association (APACMed)!
Founded in 2014, the Asia Pacific Medical Technology Association (APACMed) represents manufacturers and suppliers of medical equipment, devices and in-vitro […]
- Chemopharm announces expanded distribution partnership with Mindray in Malaysia
April, 2019 – Chemopharm Sdn Bhd, an Everlife investment and leading laboratory and medical devices distributor headquartered in Malaysia, is […]
- CPC Diagnostics and YHLO jointly launch iFlash CLIA System in India
April 2019 – CPC Diagnostics, a leading IVD manufacturer and distributor in India, and YHLO, a leading company for immunoassays […]
- Everstone-backed Everlife invests in Chennai based CPC Diagnostics
Mumbai, March 13, 2019 – The Everstone Group via its healthcare platform Everlife has acquired a stake in Chennai based CPC […]
- Everstone invests in Chemopharm, a leading Southeast Asian distributor of medical products and solutions
Originally published on Everstone website here. Singapore, November 23, 2017 – The Everstone Group via its platform Everlife has acquired Malaysia-based […]
- Case Study: Achieving success through active principal management
A successful distributor-principal relationship requires effort and time to build, and benefits both parties. We are fortunate that the principals […]
